
|Videos|March 19, 2015
The Role of High-Dose IL-2 in RCC
Author(s)Mario Sznol, MD
Mario Sznol, MD, professor of medicine, Yale Cancer Center, discusses the role of high-dose IL-2 for the treatment of renal cell carcinoma (RCC).
Clinical Pearls
Mario Sznol, MD, professor of medicine, Yale Cancer Center, discusses the role of high-dose IL-2 for the treatment of renal cell carcinoma (RCC).
- There is still a role for high-dose IL-2 in RCC.
- Anti-PD-1 agents are active, but a different population of patients may respond to high-dose IL-2.
- Both agents are necessary to achieve durable remissions.
- If combinations with anti-PD-1 agents prove to be active, IL-2 may be moved to the second- or third-line.







































